Jiangsu Vcare Wholly-owned Subsidiary Nanjing Vcare Successfully Acquired Hubei Tianshu Pharmaceutical

2022-05-06

Recently, Nanjing Vcare PharmaTech Co., Ltd. (hereinafter referred to as "Nanjing Vcare"), a wholly owned subsidiary of Jiangsu Vcare PharmaTech Co., Ltd. (hereinafter referred to as "Jiangsu Vcare"), signed a merger agreement with Hubei Tianshu Pharmaceutical Co., Ltd. (hereinafter referred to as "Tianshu Pharmaceutical"), Nanjing Vcare completed the merger and acquisition of Tianshu Pharmaceuticaland has completed industrial and commercial change registration. Tianshu Pharmaceutical will take an important link in the layout of the whole industrial chain of "Chemistry + Pharmacy + Medicine" as a subordinate manufacturing site of Nanjing Vcare, further improve the ability of Nanjing Vcare CRO/CDMO to serve the whole industrial chain, and enhance the comprehensive competitiveness of the company.

 

 

△天舒药业厂区原貌

 

 

△天舒工厂现有车间及生产设备（在建中）

 

Tianshu Pharmaceutical was established in 2016 and is located in Xiangyang (Yicheng) Fine Chemical Industrial Park, Hubei Provincial Chemical Park, covering an area of 130 mu, has built 80 mu. It is specialized in the production and sales of pharmaceutical intermediates and APIs. The products have been exported to South Korea, Europe and the United States and other places, and have high popularity and good reputation in the industry. Tianshu Pharmaceutical has a total of 14 utility model patents, 2 invention patents, and is applying for 2 international patents, which are now high-tech enterprises in Hubei Province.

 

 

△天舒药业工厂鸟瞰图

 

After the merger and acquisition, Tianshu Pharmaceutical will continue to build on the basis of the original workshop and production line. The first phase of engineering capacity includes an API production workshop and an intermediate production workshop. The construction area of API workshop is 2,000㎡, including a non-cytotoxic tumor line and a common line, with a total of 34 reactors and a production capacity of about 55 m ³; the construction area of intermediate workshop is 3,000 ㎡, including 5 production lines (including a hydrogenation line), equipped with 100 reactors at high and low temperature and hydrogenation, with a production capacity of about 300 m ³.Facilities will be designed and constructed in strict accordance with FDA and cGMP requirements to meet high-end customer requirements. Nanjing Vcare will push the plant to start at full speed, and the first workshop is planned to be put into production at the end of September.

 

The cooperation between Nanjing Vcare and Tianshu Pharmaceutical will fully realize the complementary advantages, assist the development and promotion of the original products of Tianshu Pharmaceutical, effectively break the bottleneck of Nanjing Vcare capacity, and improve the efficiency of switching from R & D to production. At the same time, Nanjing Vcare has ploughed more than 10 years of experience and good customer base in the field of CRO/CDMO, gathered the resource advantages of intermediates and APIs, introduced green chemical technologies such as continuous flow, micro filling bed, metal catalysis, and bio enzyme catalysis, opened up the whole industrial chain R & D and CDMO production services, strengthened strategic cooperation with domestic and foreign pharmaceutical enterprises, and made Nanjing Vcare a first-class "chemistry + pharmacy + medicine" one-stop whole industrial chain R & D service and production platform.

 

Dr. Yanchun Gong, co-founder and CEO of Jiangsu Vcare, said: "Thank you to the relevant leaders of Hubei Yangtze River Industry Investment Group, Xiangyang and Yicheng for their strong support and create good conditions for the rapid landing of the project. This merger and acquisition of Tianshu Pharmaceutical reflects our determination to improve production capacity, introduce new technologies and help partners continue to succeed, which is conducive to improving the overall operation and management of Vcare and multi-regional capacity layout ability and will certainly become one of the important milestones in the development of the company. We hope to give back customers' trust in us with quality service ability and carefully deliver each project entrusted by customers. "

Prev

Nanjing Vcare Won the Title of "Excellent Strategic Cooperation Supplier of Kelun Pharmaceutical in 2021"

Next

Nanjing Vcare was Recognized as a "Small and Medium-sized Science and Technology Enterprise in Jiangsu Province"